This profile is for informational purposes only and is not medical advice. Consult a healthcare professional before use. See full terms.
Tianeptine
An atypical antidepressant with a unique glutamatergic and mu-opioid receptor mechanism that promotes hippocampal neuroplasticity, enhances stress resilience, and improves cognitive function under depressive conditions - prescribed in over 60 countries as Stablon and Coaxil.
Benefits
What is Tianeptine?
Tianeptine is a clinically approved atypical antidepressant that defies conventional classification. Originally developed by the French pharmaceutical company Servier in the 1960s and marketed since the 1980s, it was initially believed to be a selective serotonin reuptake enhancer (SSRE) - the pharmacological opposite of SSRIs. However, modern research has revealed that tianeptine's primary mechanisms involve mu-opioid receptor (MOR) agonism and glutamatergic modulation, with profound effects on hippocampal neuroplasticity. A landmark 2014 study by Gassaway et al. published in Translational Psychiatry confirmed tianeptine as a full agonist at mu-opioid and delta-opioid receptors, fundamentally reshaping our understanding of its pharmacology.
As a nootropic, tianeptine is valued for its ability to reverse stress-induced neuronal atrophy in the hippocampus and amygdala, restore synaptic plasticity, and enhance BDNF (brain-derived neurotrophic factor) expression. Unlike SSRIs, which can cause cognitive blunting and emotional flattening, tianeptine tends to preserve or enhance cognitive function. A 2001 study by Klasik et al. demonstrated significant improvements in attention, psychomotor speed, and memory in depressed patients treated with tianeptine compared to fluoxetine. Its glutamatergic mechanism - specifically modulation of AMPA and NMDA receptor signalling - positions it as a compound that directly supports the neurobiological substrates of learning and memory.
- Mu-opioid receptor agonism: Acts as a full agonist at mu-opioid receptors, contributing to its antidepressant and anxiolytic effects through modulation of reward and emotional processing circuits
- Glutamatergic modulation: Normalises stress-disrupted glutamate transmission, restoring AMPA receptor signalling and NMDA receptor function in the hippocampus and prefrontal cortex
- Hippocampal neuroplasticity: Reverses stress-induced dendritic atrophy in CA3 hippocampal neurons and restores neurogenesis, directly counteracting the structural brain changes caused by chronic stress
- BDNF enhancement: Upregulates brain-derived neurotrophic factor expression, supporting neuronal survival, synaptic strengthening, and long-term potentiation critical for memory formation
- HPA axis normalisation: Reduces elevated cortisol and CRF (corticotropin-releasing factor) levels, restoring healthy hypothalamic-pituitary-adrenal axis function disrupted by chronic stress
- Standard clinical dosage: 12.5 mg three times daily (37.5 mg total per day), the dose used in virtually all clinical trials and approved prescribing guidelines
- Sodium form: Tianeptine sodium is the original pharmaceutical form with rapid absorption and shorter duration, requiring three-times-daily dosing
- Sulfate form: Tianeptine sulfate has slower absorption and longer half-life, often dosed at 25 mg twice daily for more sustained effects
- Nootropic use: Many nootropic users employ 12.5 mg once or twice daily rather than the full clinical dose, reporting cognitive and mood benefits at lower amounts
- Timing: Take before meals for optimal absorption. Tianeptine sodium reaches peak plasma concentration within 1-2 hours
- Addiction potential: The mu-opioid receptor agonism creates genuine abuse liability, particularly with the sodium form at doses exceeding clinical guidelines. Cases of dependence and withdrawal have been documented at doses of 100 mg or more per day
- Regulatory status: Prescription medication in Europe, Asia, and Latin America. Unscheduled but increasingly regulated in the US - banned in several states including Michigan, Alabama, and Minnesota due to abuse concerns
- Withdrawal symptoms: Abrupt cessation after prolonged high-dose use can produce opioid-like withdrawal including anxiety, insomnia, muscle aches, and irritability. Taper gradually under medical supervision
- Drug interactions: Do not combine with MAOIs, other opioid agonists, or CNS depressants. Caution with serotonergic drugs due to potential for serotonin syndrome at high doses
- Hepatic considerations: Primarily metabolised by the liver via beta-oxidation. Dose reduction recommended in patients with severe hepatic impairment or those over 70 years of age
Natural Sources & Forms
- Pharmaceutical (Stablon/Coaxil): Available by prescription in France, Russia, India, and over 60 other countries as 12.5 mg tablets
- Tianeptine sodium: Available as a research chemical or supplement in some jurisdictions, typically sold as powder or capsules
- Tianeptine sulfate: An alternative salt form with extended duration, popular in the nootropics community for its smoother pharmacokinetic profile
- Tianeptine free acid: The least common form, with the slowest absorption and longest duration of action
- Quality concerns: When sourcing outside the pharmaceutical supply chain, third-party testing for purity and accurate dosing is essential due to the compound's potency and abuse potential
Frequently Asked Questions
An atypical antidepressant with a unique glutamatergic and mu-opioid receptor mechanism that promotes hippocampal neuroplasticity, enhances stress resilience, and improves cognitive function under depressive conditions - prescribed in over 60 countries as Stablon and Coaxil.
The key benefits of Tianeptine include: Anxiety & Calm, Cognitive Enhancement, Focus, Memory, Mood, Motivation, Stress Relief.
Mu-opioid receptor agonism: Acts as a full agonist at mu-opioid receptors, contributing to its antidepressant and anxiolytic effects through modulation of reward and emotional processing circuits Glutamatergic modulation: Normalises stress-disrupted glutamate transmission, restoring AMPA receptor signalling and NMDA receptor function in the hippocampus and prefrontal cortex Hippocampal neuroplasticity: Reverses stress-induced dendritic atrophy in CA3 hippocampal neurons and restores neurogenesis, directly counteracting the structural brain changes caused by chronic stress BDNF enhancement: Upregulates brain-derived neurotrophic factor expression, supporting neuronal survival, synaptic strengthening, and long-term potentiation critical for memory formation HPA axis normalisation: Reduces elevated cortisol and CRF (corticotropin-releasing factor) levels, restoring healthy hypothalamic-pituitary-adrenal axis function disrupted by chronic stress
Standard clinical dosage: 12.5 mg three times daily (37.5 mg total per day), the dose used in virtually all clinical trials and approved prescribing guidelines Sodium form: Tianeptine sodium is the original pharmaceutical form with rapid absorption and shorter duration, requiring three-times-daily dosing Sulfate form: Tianeptine sulfate has slower absorption and longer half-life, often dosed at 25 mg twice daily for more sustained effects Nootropic use: Many nootropic users employ 12.5 mg once or twice daily rather than the full clinical dose, reporting cognitive and mood benefits at lower amounts Timing: Take before meals for optimal absorption. Tianeptine sodium reaches peak plasma concentration within 1-2 hours
Addiction potential: The mu-opioid receptor agonism creates genuine abuse liability, particularly with the sodium form at doses exceeding clinical guidelines. Cases of dependence and withdrawal have been documented at doses of 100 mg or more per day Regulatory status: Prescription medication in Europe, Asia, and Latin America. Unscheduled but increasingly regulated in the US - banned in several states including Michigan, Alabama, and Minnesota due to abuse concerns Withdrawal symptoms: Abrupt cessation after prolonged high-dose use can produce opioid-like withdrawal including anxiety, insomnia, muscle aches, and irritability. Taper gradually under medical supervision Drug interactions: Do not combine with MAOIs, other opioid agonists, or CNS depressants. Caution with serotonergic drugs due to potential for serotonin syndrome at high doses Hepatic considerations: Primarily metabolised by the liver via beta-oxidation. Dose reduction recommended in patients with severe hepatic impairment or those over 70 years of age
Overall Rating
Log in to rate this nootropic.
Comments
Log in to leave a comment.
No comments yet. Be the first to share your experience!